Document is current
Any future updates will be listed below
-
Authors
Al-Jeffery, Abdullah
Zeng, Feier
Sophocleous, Antonia
Marino, Silvia
Ponzetti, Marco
Capulli, Mattia
Paul, Andrew
Plevin, Robin
Fowles, Ann C. M.
Mackay, Simon P.
Rucci, Nadia
Idris, Aymen I. https://orcid.org/0000-0003-4327-5306
-
Funding
Funding for this research was provided by:
Cancer Research UK (A9336)
Prostate Cancer UK (PG12-27)
- License Information
-
More Information
Article History
Received: 12 November 2025
Accepted: 28 May 2026
First Online: 25 July 2026
Declarations
Conflict of interest: A.I. Idris is a founder and shareholder of ArthElix Ltd. (UK, registration No: SC288265), a company established to develop novel TRAF/ NFκB inhibitors as anti-rheumatic and anti-metastatic drugs. Simon P. Mackay is an inventor on a patent concerning the use of the first-in-class IKK α inhibitors described for the treatment of cancer. Other authors declare no conflict of interest.
